Kadcyla ‘price remains too high’, says NICE
17 November 2015 | By Victoria White
NICE has published final draft guidance not recommending the use of Kadcyla as a treatment for a type of advanced breast cancer because the price is too high...
List view / Grid view
News
Futura provides update on efficacy study of MED2002
17 November 2015 | By Victoria White
MED2002 is the Company’s novel gel for the treatment of erectile dysfunction...
Novartis announces new trial results for Ultibro Breezhaler in COPD
17 November 2015 | By Victoria White
Once-daily Ultibro Breezhaler met its primary endpoint (non-inferiority) and also demonstrated superiority to twice-daily Seretide...
AbbVie releases new data on ABT-493 and ABT-530 in HCV
16 November 2015 | By Victoria White
The data show high rates of sustained virologic response at 12 weeks post-treatment in non-cirrhotic patients with chronic hepatitis C virus infection...
CI Precision announces new release of its MES
16 November 2015 | By CI Precision
CI Precision, global supplier of MES and weight sorting solutions, announces the release of version 6 of Ci-DMS, their manufacturing execution system (MES) which has gained established use in pharmaceuticals production...
Study prompts rethink on the rise of diabetes in cities
16 November 2015 | By Victoria White
New research shows socio-cultural factors including time pressure, commuting time and where you live play significant roles in diabetes vulnerability...
WHO releases survey on antibiotic resistance
16 November 2015 | By Victoria White
WHO's multi-country survey reveals people are confused about antibiotic resistance and do not understand how to prevent it from growing...
Elbasvir/grazoprevir demonstrates sustained virologic response in HCV
16 November 2015 | By Victoria White
The results come from a trial evaluating elbasvir/grazoprevir in patients with HCV infection who are receiving opioid agonist therapy...
AbbVie announces new data for Viekira Pak in HCV
16 November 2015 | By Victoria White
Results announced show that 95% of patients achieved a sustained virologic response at 12 weeks post-treatment...
FDA approves haemophilia A treatment Adynovate
16 November 2015 | By Victoria White
Adynovate has been shown to reduce the number of bleeding episodes during routine care...
FDA approves Tagrisso for non-small cell lung cancer
13 November 2015 | By Victoria White
Tagrisso (AZD9291) is the only approved medicine indicated for patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer...
Imbruvica Phase III combination data submitted to the FDA
13 November 2015 | By Victoria White
AbbVie has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for labelling considerations based on safety and efficacy results from the Phase III HELIOS trial investigating the use of Imbruvica (ibrutinib) plus bendamustine and rituximab (BR) versus placebo plus BR in relapsed or…
2015 global measles vaccination milestones off track, says WHO
13 November 2015 | By Victoria White
New data shows that overall progress towards increasing global immunisation coverage has recently stagnated...
ESCMID highlights projects in the fight against antimicrobial resistance
13 November 2015 | By Victoria White
Ahead of the European Antibiotic Awareness Day, ESCMID has highlighted two of its more recent projects in the fight against antimicrobial resistance...
EC grants Marketing Authorisation for Obizur
13 November 2015 | By Victoria White
Obizur is the first recombinant porcine sequence FVIII treatment available in Europe to treat acquired haemophilia A...
